Ekso Bionics (NASDAQ:EKSO) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a note issued to investors on Tuesday. The firm set a “hold” rating on the stock.

A number of other research firms have also weighed in on EKSO. HC Wainwright reduced their price objective on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. Lake Street Capital reduced their price target on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, October 29th.

Ekso Bionics Stock Performance

Shares of EKSO stock opened at $0.65 on Tuesday. The company has a current ratio of 2.81, a quick ratio of 2.14 and a debt-to-equity ratio of 0.28. The company’s fifty day moving average price is $0.69 and its 200-day moving average price is $0.95. The stock has a market cap of $14.30 million, a PE ratio of -1.00 and a beta of 1.47. Ekso Bionics has a 12 month low of $0.50 and a 12 month high of $2.50.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The business had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. During the same quarter last year, the company posted ($0.24) EPS. On average, equities analysts expect that Ekso Bionics will post -0.48 EPS for the current fiscal year.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.